Compare Kroger Co (KR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs TG Therapeutics Inc — how do they compare? Kroger Co trades at $56.01 (market cap $34.46B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Kroger Co is far larger — about 4.5× TG Therapeutics Inc's market cap, and Kroger Co pays a 2.56% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| KR | TGTX | |
|---|---|---|
Market Cap | $34.46B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $59.06 |
52-Week Low | $55.53 | $26.94 |
Enterprise Value | $54.56B | $7.84B |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $56.09, down 0.69% on the day, with a bearish technical signal from moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates by $0.01, but beat in the prior two quarters. Revenue for 2025 was $147.12 billion with a net income margin of 0.71%. Recent news includes the appointment of a new Chief eCommerce Officer and expanded prescription delivery services, signaling digital growth initiatives.
The stock presents a valuation gap with a consensus price target of $68.25, implying 22% upside, supported by a 47.7% buy rating from analysts. However, risks include competitive pressures in grocery retail, a high P/E ratio of 32.89, and a projected net income decline in 2026. Positive cash flow trends and dividend payments offer stability, but execution on e-commerce strategy is critical for sustained growth.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
